Navigation Links
GlaxoSmithKline Accelerates Review of Exelixis' XL880
Date:8/23/2007

- Early review expected to facilitate rapid advancement of leading MET

inhibitor into later stage clinical studies -

SOUTH SAN FRANCISCO, Calif., Aug. 23 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today announced that it has agreed to a request from GlaxoSmithKline (GSK) to initiate its review of XL880 before the compound reaches proof-of-concept. Exelixis expects to deliver the appropriate diligence information to GSK in mid-September, at which point GSK will begin its review to determine whether or not to select XL880 for further development and commercialization. Both companies have agreed to expedite the review of XL880 in order to build on its position as a leading MET inhibitor, which is believed to be the most advanced in clinical development. Under the terms of the product development and commercialization agreement between the parties, GSK's review period would have otherwise commenced once proof-of-concept data became available. In addition, the companies have initiated preliminary transition activities in the event that GSK decides to select XL880 for further clinical development and commercialization.

"We are extremely pleased that GSK has asked us to expedite its review process for XL880. This request reflects the high level of excitement around both the compound and the therapeutic potential of MET inhibition," said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. "Our recently reported data from the XL880 Phase 1 trial at the 2007 ASCO Annual Meeting underscore our belief that XL880 is the most advanced MET inhibitor in clinical development, and we and GSK are committed to building upon this leadership position."

About XL880


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. GlaxoSmithKline and Genmab Present Positive Phase II Results With ofatumumab in Patients With Rheumatoid Arthritis (RA)
2. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
3. New Data on Genmab and GlaxoSmithKlines Ofatumumab: Phase II Study in Rheumatoid Arthritis to be Presented at EULAR
4. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
5. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
6. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
7. Medicures MEND-CABG Trial Results Published in Peer Reviewed Journal
8. Review of Nexavar Data Presented at ASCO 2007- Investor Conference Call on June 4, 2007
9. Salix Pharmaceuticals Previews Digestive Disease Week 2007
10. Reatas Synthetic Triterpenoids Profiled in Nature Reviews Cancer
11. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015 The North ... at a CAGR of 7.9% from 2014 to 2019. ... ) command larger shares in the dermatology diagnostic ... to grow at the highest CAGR of 9.8% during ... devices market is driven by factors such as rising ...
(Date:4/21/2015)... This report analyzes the worldwide markets for ... Equipment for Therapeutic Apheresis, and Equipment for Donor Apheresis. ... Plasmapheresis, Plateletpheresis, and Others. The report provides separate comprehensive ... Japan , Europe ... World. Annual estimates and forecasts are provided for the ...
(Date:4/21/2015)... According to a new ... Cell, Blood, Gene Therapy), Product (Instruments, Services, Kits, ... Residual Contamination, Adventitious Agents) - Global Forecast to ... Testing Market was valued at $1,758.69 Million in ... a CAGR of 12.23% to reach $3,130.85 Million ...
Breaking Medicine Technology:North American Dermatology Diagnostic Devices Market by Diagnostic Device, by Treatment Device, by Application - Forecast to 2019 2North American Dermatology Diagnostic Devices Market by Diagnostic Device, by Treatment Device, by Application - Forecast to 2019 3World Apheresis Equipment Industry 2World Apheresis Equipment Industry 3World Apheresis Equipment Industry 4World Apheresis Equipment Industry 5World Apheresis Equipment Industry 6World Apheresis Equipment Industry 7World Apheresis Equipment Industry 8World Apheresis Equipment Industry 9World Apheresis Equipment Industry 10World Apheresis Equipment Industry 11World Apheresis Equipment Industry 12World Apheresis Equipment Industry 13World Apheresis Equipment Industry 14World Apheresis Equipment Industry 15World Apheresis Equipment Industry 16World Apheresis Equipment Industry 17World Apheresis Equipment Industry 18World Apheresis Equipment Industry 19World Apheresis Equipment Industry 20World Apheresis Equipment Industry 21Biologics Safety Testing Market Worth $3,130.85 Million by 2019 2Biologics Safety Testing Market Worth $3,130.85 Million by 2019 3Biologics Safety Testing Market Worth $3,130.85 Million by 2019 4
... Sept. 14 ThermoGenesis Corp. (Nasdaq: KOOLD ), ... and store adult stem cells, said today that revenues for ... revenues of $4.0 million for the same quarter a year ... $4.8 million. The Company recorded disposable revenues of ...
... WALTHAM, Mass., Sept. 14, 2010 Amylin Pharmaceuticals, Inc. ... (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: ... research findings on BYETTA® (exenatide) injection and the investigational ... presented at the 46th Annual Meeting of the European ...
Cached Medicine Technology:ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 2ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 3ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 4ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 5ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 6ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 7BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 2BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 3BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 4BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 5BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 6BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 7
(Date:4/21/2015)... has released a new blog post explaining how to find ... SUVs are large vehicles that fare well in crash tests. ... regular car shows that passengers from the first car have ... crashes, but these large vehicles may be unstable and they ... now possible to find low cost car insurance plans on ...
(Date:4/21/2015)... Carinsurancehints.com has released a new blog ... impact on auto insurance prices . , ... prices. Clients should review their insurance options before deciding ... under several forms. Some of the popular policies provide ... compare online rates and find the best prices in ...
(Date:4/21/2015)... April 21, 2015 Respected academic institution ... strategy , Visage Imaging Inc. (“Visage”), a wholly ... has signed a seven-year contract with University of Florida ... Florida. The deal furthers the penetration of ... a key area of the North American enterprise imaging ...
(Date:4/21/2015)... Now in its fifteenth year, ... to unite over 3,000 senior attendees from across ... Suburban Collection Showplace on June 3 and 4. ... Ford, and Kia are set to deliver headline ... is reshaping automotive as connectivity paves the way ...
(Date:4/21/2015)... According to a recent article published by ... made naloxone available for anyone to have access to. ... without a doctor’s order- in an attempt to reduce ... state police will also begin carrying naloxone on hand. ... an opiate overdose reversal medication. The medicine helps relieve ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Quotes For SUVs Are Available Online 2Health News:Heavily Circulated Roads Can increase Auto Insurance Costs 2Health News:Visage Imaging Signs University of Florida Health 2Health News:Visage Imaging Signs University of Florida Health 3Health News:Visage Imaging Signs University of Florida Health 4Health News:TU-Automotive Detroit 2015 Sample Attendee List Released 2Health News:TU-Automotive Detroit 2015 Sample Attendee List Released 3Health News:Drug Rehab Philadelphia Comments on Gov. Wolf’s Decision to Make Naloxone Widely Available 2
... can have a significantly beneficial effect in patients with ... randomize emphysema patients to receive either LVRS or non-surgical ... good treatment alternative for selected emphysema patients since it ... of life for a period of at least five ...
... , , SAN FRANCISCO, July ... gay, lesbian, bisexual, and transgender civil rights organization, today announced ... on Saturday, July 25, 2009, at the Westin St. Francis ... Progress," speakers will discuss issues impacting the LGBT community,s strive ...
... EATONTOWN, N.J., July 23 Osteotech, Inc. (Nasdaq: ... of biologic products for regenerative healing, announced today that the ... be released Wednesday, July 29, 2009. The management team of ... July 30, 2009, at 10:00 a.m. (EDT) to discuss the ...
... , , , , ... , , SAN DIEGO, July 23 /PRNewswire-FirstCall/ ... focused on developing products for minimally disruptive surgical treatments for the spine, announced today ... NuVasive reported second quarter revenue of $88.5 million, a 54.1% increase over ...
... , , WASHINGTON, July 23 ... that advocates for cancer patients and community providers of cancer care, ... saying: , , "We strongly ... on what works and fix what is broken., Unfortunately, that is ...
... MOUNTAIN VIEW, Calif., July 23 Omnicell, Inc. (Nasdaq: ... announced results for its second quarter ended June 30, 2009. , ... of 2009 was $52.6 million, up $0.4 million or 0.8% from the first ... of 2008. , , Second quarter ...
Cached Medicine News:Health News:Lung volume reduction surgery shown to prolong and improve life for some emphysema patients 2Health News:Human Rights Campaign Announces Speakers at 25th Annual Bay Area Gala 2Health News:Human Rights Campaign Announces Speakers at 25th Annual Bay Area Gala 3Health News:Osteotech Announces Second Quarter 2009 Financial Results Release and Conference Call 2Health News:NuVasive Reports Second Quarter 2009 Financial Results 2Health News:NuVasive Reports Second Quarter 2009 Financial Results 3Health News:NuVasive Reports Second Quarter 2009 Financial Results 4Health News:NuVasive Reports Second Quarter 2009 Financial Results 5Health News:NuVasive Reports Second Quarter 2009 Financial Results 6Health News:NuVasive Reports Second Quarter 2009 Financial Results 7Health News:NuVasive Reports Second Quarter 2009 Financial Results 8Health News:NuVasive Reports Second Quarter 2009 Financial Results 9Health News:NuVasive Reports Second Quarter 2009 Financial Results 10Health News:NuVasive Reports Second Quarter 2009 Financial Results 11Health News:NuVasive Reports Second Quarter 2009 Financial Results 12Health News:The Community Oncology Alliance Responds to President Obama's Press Conference Comments Regarding Cancer Patients 2Health News:The Community Oncology Alliance Responds to President Obama's Press Conference Comments Regarding Cancer Patients 3Health News:The Community Oncology Alliance Responds to President Obama's Press Conference Comments Regarding Cancer Patients 4Health News:Omnicell Announces Second Quarter 2009 Results 2Health News:Omnicell Announces Second Quarter 2009 Results 3Health News:Omnicell Announces Second Quarter 2009 Results 4Health News:Omnicell Announces Second Quarter 2009 Results 5Health News:Omnicell Announces Second Quarter 2009 Results 6Health News:Omnicell Announces Second Quarter 2009 Results 7Health News:Omnicell Announces Second Quarter 2009 Results 8Health News:Omnicell Announces Second Quarter 2009 Results 9Health News:Omnicell Announces Second Quarter 2009 Results 10Health News:Omnicell Announces Second Quarter 2009 Results 11Health News:Omnicell Announces Second Quarter 2009 Results 12
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: